Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-884-5 | CAS number: 1154308-86-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on the oral and dermal LD50 values, the test substance is considered to have a low acute toxicity potential.a moderate acute toxicity potential.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK, Margate
- Age at study initiation: 8 to 10 weeks
- Fasting period before study: Overnight on the day before dosing
- Housing: 3 per cage
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 21°C
- Humidity (%): 46% to 59%
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: To: 17 July 2012 to 11 September 2012 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 2.2 mL/kg
DOSAGE PREPARATION (if unusual):
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Acute Toxicity on Sponsor's Safety Data Sheet stated that the oral LD50 in rats is >5000 mg/kg
The test item was administered as supplied (ie not formulated in a vehicle)
MAXIMUM DOSE VOLUME APPLIED: 2.2 mL/kg
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The Acute Toxicity Data section of the Sponsor's Safety Data Sheet stated that the acute oral LD50 in rats is >5000 mg/kg - Doses:
- 300 mg/kg and 2000 mg/kg
- No. of animals per sex per dose:
- 6 at 300 mg/kg and 6 at 2000 mg/kg
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations at least 5 times on the day of dosing, then daily for 14 days. Body weights on Days 1, 8 and 15
- Necropsy of survivors performed: yes (also decedents)
- Other examinations performed: none - Statistics:
- None
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: Two of 6 animals given 2000 mg/kg bw were euthanized during the study.
- Mortality:
- Two of the 6 animals that were treated with the substance at a dose level of 2000 mg/kg (Group 2 Animal Nos. 6 and 4) were euthanised at approximately 3½ h and 5¾ h post dose, respectively, because of the severity of their clinical signs.
There were no deaths among the Group 1 animals treated with the substance at a dose level of 2000 mg/kg or among the 6 animals that received the 300 mg/kg dose level (Groups 3 and 4). - Clinical signs:
- other: All 6 animals treated at 2000 mg/kg displayed subdued behaviour and rolling gait within approximately 15 min of dosing and all were prostrate within approximately 30 min. Five of these animals displayed hunched posture, piloerection and staggering and 5
- Gross pathology:
- Necropsy revealed no macroscopic abnormalities in any animal.
- Other findings:
- None
- Interpretation of results:
- other: Category 4 based on CLP criteria
- Conclusions:
- Under the conditions of the study, the oral LD50 value was considered to be 2000 mg/kg bw, indicating low acute oral toxicity potential.
- Executive summary:
A study was conducted to determine the acute oral toxicity of the test substance, in Sprague-Dawley rats according to OECD Guideline 423, in compliance with GLP. Two groups of six fasted females were treated with the test substance at a dose level of and 2000 (Group 1 and 2) and 300 mg/kg bw (Group 3 and 4). The animals were observed for up to 14 days after the day of dosing. The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight changes, and gross necropsy findings. Two of the 6 animals that were treated with the substance at a dose level of 2000 mg//kg bw (Group 2) bw were euthanised at approximately 3½ h and 5¾ h post dose, respectively, because of the severity of their clinical signs. Signs were noted in these animals from 5 min post dose and at time of euthanasia included respiratory difficulties, unresponsiveness, watery discharge from the eyes and coldness to the touch. All 6 animals treated at 2000 mg/kg bw displayed subdued behaviour and rolling gait and were prostrate within approximately 30 min of dosing. Other signs noted in Day 1 included hunched posture, piloerection, staggering and slow and irregular respiration. Lowered body posture was recorded in all of these animals during the first 2 days of the observation period. Among surviving animals, the majority of these signs had resolved by Day 2 and all had resolved by Day 3. In animals treated at 300 mg/kg bw the clinical signs on Day 1 included subdued behaviour, hunched posture, staggering, piloerection and partial eye closure. All signs had resolved by Day 2. The body weight gains of animals treated at 300 mg/kg bw were considered to be acceptable for rats of this age and strain. Lower body weight gains were recorded in surviving animals treated at 2000 mg/kg bw. No macroscopic abnormalities were recorded in any of the animals at necropsy. Under the conditions of the study, the oral LD50 value was considered to be 2000 mg/kg bw (Robertson, 2012).
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- ca. 2 000 mg/kg bw
- Quality of whole database:
- adequate
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- other: Acute Dermal Toxicity
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK, Margate
- Age at study initiation: 8 to 10 weeks
- Weight at study initiation: 241.4 g to 292.9 g
- Fasting period before study: Not applicable
- Housing: Single housing
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad liibitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Approximately 20°C
- Humidity (%): 47% to 57%
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: To: 31 July 2012 to 21 August 2012 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Approximately 12.6 cm2
- % coverage: 3.3% to 3.6% of body surface
- Type of wrap if used: Semi-occlusive tape ("Micropore") and non-irritating occlusive tape ("Sleek")
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Sterile water
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2.2 mL/kg
- Constant volume or concentration used: yes - Duration of exposure:
- 24 hrs
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males, 5 females
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations at least 5 times on the day of dosing, then daily for 14 days. Body weights on Days 1, 8 and 15
- Necropsy of survivors performed: yes - Statistics:
- No
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No deaths occurred at this dose.
- Mortality:
- There were no unscheduled deaths during the study.
- Clinical signs:
- other: There were no signs of systemic toxicity and no local findings at the dose sites of any animal at any observation timepoint.
- Gross pathology:
- Macroscopic findings at necropsy were restricted to dark foci to all lobes of the lungs of one female, Animal No. 7. This finding is commonly observed in rats of this strain and age at these laboratories and is not considered to be related to administration of the substance.
- Interpretation of results:
- other: CLP criteria not met
- Conclusions:
- Under the conditions of the study, the dermal LD50 value of the test substance in Sprague-Dawley rats was estimated to be greater than 2000 mg/kg bw.
- Executive summary:
A study was conducted to determine the acute dermal toxicity of the test substance, in Sprague-Dawley rats according to OECD Guideline 402, in compliance with GLP. A group of ten animals (five males and five females) was given a single, 24 h, occluded dermal application of the test substance to intact skin at a dose level of 2000 mg/kg bw. Animals were observed for signs of reaction to treatment from the day of dosing until the end of the observation period on Day 15. Body weights were recorded weekly and all animals were subjected to a necropsy examination. There were no unscheduled deaths. There were no systemic signs and no local findings at the dose sites noted in any animal at any observation timepoint. Body weight gain was considered to be acceptable for rats of this age and strain. No macroscopic abnormalities attributable to treatment with the substance were recorded at necropsy. Under the conditions of the study, the median lethal dermal dose level (LD50) was determined to be greater than 2000 mg/kg bw (Robertson, 2012).
.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 2 000 mg/kg bw
- Quality of whole database:
- experimental result by guideline method under GLP
Additional information
Oral:
A study was conducted to determine the acute oral toxicity of the test substance, in Sprague-Dawley rats according to OECD Guideline 423, in compliance with GLP. Two groups of six fasted females were treated with the test substance at a dose level of and 2000 (Group 1 and 2) and 300 mg/kg bw (Group 3 and 4). The animals were observed for up to 14 days after the day of dosing. The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight changes, and gross necropsy findings. Two of the 6 animals that were treated with the substance at a dose level of 2000 mg//kg bw (Group 2) bw were euthanised at approximately 3½ h and 5¾ h post dose, respectively, because of the severity of their clinical signs. Signs were noted in these animals from 5 min post dose and at time of euthanasia included respiratory difficulties, unresponsiveness, watery discharge from the eyes and coldness to the touch. All 6 animals treated at 2000 mg/kg bw displayed subdued behaviour and rolling gait and were prostrate within approximately 30 min of dosing. Other signs noted in Day 1 included hunched posture, piloerection, staggering and slow and irregular respiration. Lowered body posture was recorded in all of these animals during the first 2 days of the observation period. Among surviving animals, the majority of these signs had resolved by Day 2 and all had resolved by Day 3. In animals treated at 300 mg/kg bw the clinical signs on Day 1 included subdued behaviour, hunched posture, staggering, piloerection and partial eye closure. All signs had resolved by Day 2. The body weight gains of animals treated at 300 mg/kg bw were considered to be acceptable for rats of this age and strain. Lower body weight gains were recorded in surviving animals treated at 2000 mg/kg bw. No macroscopic abnormalities were recorded in any of the animals at necropsy. Under the conditions of the study, the oral LD50 value was considered to be 2000 mg/kg bw.
Dermal:
A study was conducted to determine the acute dermal toxicity of the test substance, in Sprague-Dawley rats according to OECD Guideline 402, in compliance with GLP. A group of ten animals (five males and five females) was given a single, 24 h, occluded dermal application of the test substance to intact skin at a dose level of 2000 mg/kg bw. Animals were observed for signs of reaction to treatment from the day of dosing until the end of the observation period on Day 15. Body weights were recorded weekly and all animals were subjected to a necropsy examination. There were no unscheduled deaths. There were no systemic signs and no local findings at the dose sites noted in any animal at any observation timepoint. Body weight gain was considered to be acceptable for rats of this age and strain. No macroscopic abnormalities attributable to treatment with the substance were recorded at necropsy. Under the conditions of the study, the median lethal dermal dose level (LD50) was determined to be greater than 2000 mg/kg bw (Robertson, 2012).
Inhalation:
Given the low vapour pressure of the substance (VP = 1.9E-4 Pa at 25°C), which is well below the cut-off of 0.01 Pa as per the ECHA Guidance R.7a, the test substance is considered to have low volatility potential. In case inhalable forms of the substance (either pure or in aqueous solutions) are created under particular conditions (e.g., spraying, elevated temperature/pressure), appropriate risk management measures (due to corrosive nature of the test substance) such as closed systems, exhaust ventilation or wearing of respirators are implemented to control exposure. Under such conditions, the risk to humans following inhalation exposure can be considered minimal and further testing involving vertebrate animals may be omitted, in accordance with Annex XI (1.2) of the REACH regulation.
Justification for classification or non-classification
Based on the results from the acute oral and dermal studies, the test substance warrants an ‘Acute Tox. 4; H302: harmful if swallowed’ classification for oral route and no classification for the dermal route according to EU CLP (EC 1272/2008) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.